Defects in mucosal immunity leading to ulcerative colitis

Immunological Reviews

Volumn 206, Issue , 2005, Pages 296-305

  Targan, Stephan R ^a,b   Karp, Loren C ^a  

^a Division of Gastroenterology   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 4; VISILIZUMAB;

CLINICAL FEATURE; CROHN DISEASE; EPITHELIUM CELL; HEREDITY; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; INFLAMMATION; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SYMPTOM; T LYMPHOCYTE; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS;

ANIMALS; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA;

EID: 23344446340     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00286.x     Document Type: Review

References (78)

1. Podolsky DK. Inflammatory bowel disease (1). N Engl J Med 1991;325:928-937.
2. Podolsky DK. Inflammatory bowel disease (2). N Engl J Med 1991;325:1008-1016.
3. Targan S, Shanahan F. Inflammatory Bowel Disease: From Bench to Bedside, 1st edn. Baltimore: Williams and Wilkins, 1994.
4. Targan SR, Shanahan F, Karp LC. Inflammatory Bowel Disease: From Bench to Bedside, 2nd edn. Dordrecht: Kluwer Academic Publishers, 2004.
5. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990;86:202-210.
6. Satsangi J, Jewell DP, Rosenberg WM, Bell JI. Genetics of inflammatory bowel disease. Gut 1994;35:696-700.
7. Satsangi J, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996;347:1212-1217.
8. Mansfield JC, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106:637-642.
9. Duerr RH, Chensny LJ, Wong CT, Neigut DA. Homozygosity of an HLA Class II group haplotype is associated with pANCA-positive and familial ulcerative colitis. Gastroenterology 1995;108:A812.
10. Parkes M, Barmada MM, Satsangi J, Weeks DE, Jewell DP, Duerr RH. The IBD2 locus shows linkage heterogeneity between ulcerative colitis and Crohn disease. Am J Hum Genet 2000;67:1605-1610.
11. Toyoda H, et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993;104:741-748.
12. Hampe J, et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet 1999;64:808-816.
13. Rioux JD, et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 2000;66:1863-1870.
14. Duerr RH, Neigut DA. Molecularly defined HLA-DR2 alleles in ulcerative colitis and an antineutrophil cytoplasmic antibody-positive subgroup. Gastroenterology 1995;108:423-427.
15. Taylor KD, Rotter JI, Yang HY. Genetics of inflammatory bowel disease. In: Targan SR, Shanahan F, Karp LC, eds. Inflammatory Bowel Disease: From Bench to Bedside, 2nd edn. Dordrecht: Kluwer Academic Publishers, 2003:21-65.
16. Ahmad T, Satsangi J, McGovern D, Bunce M, Jewell DP. Review article: the genetics of inflammatory bowel disease. Aliment Pharmacol Ther 2001;15:731-748.
17. Roussomoustakaki M, et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997;112:1845-1853.
18. Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000;118:274-278.
19. van Heel DA, Carey AH, Jewell DP. Identification of novel polymorphisms in the beta7 integrin gene: family-based association studies in inflammatory bowel disease. Genes Immun 2001;2:455-460.
20. Satsangi J, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996;14:199-202.
21. Ma Y, et al. A genome-wide search identifies potential new susceptibility loci for Crohn's disease. Inflamm Bowel Dis 1999;5:271-278.
22. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003;124:521-536.
23. Shanahan F, et al. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology 1992;103:456-461.
24. Seibold F, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994;107:532-536.
25. Satsangi J, Landers CJ, Welsh KI, Koss K, Targan S, Jewell DP. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm Bowel Dis 1998;4:18-26.
26. Yang H, et al. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest 1993;92:1080-1084.
27. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10- deficient mice develop chronic enterocolitis. Cell 1993;75:263-274.
28. Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 1995;3:171-174.
29. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-1367.
30. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-261.
31. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993;75:274-282.
32. Hornquist CE, et al. G(alpha)i2-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines. J Immunol 1997;158:1068-1077.
33. Dieleman LA, Pena AS, Meuwissen SG, van Rees EP. Role of animal models for the pathogenesis and treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl 1997;223:99-104.
34. Halstensen TS, Das KM, Brandtzaeg P. Epithelial deposits of immunoglobulin G1 and activated complement co-localize with the "M(r) 40kD" putative auto-antigen in ulcerative colitis. Adv Exp Med Biol 1995;371B:1273-1276.
35. Mizoguchi E, Mizoguchi A, Chiba C, Niles JL, Bhan AK. Antineutrophil cytoplasmic antibodies in T-cell receptor alpha-deficient mice with chronic colitis. Gastroenterology 1997;113:1828-1835.
36. Fuss IJ, et al. Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humoral autoimmunity. J Immunol 1997;158:1912-1918.
37. Mizoguchi A, Mizoguchi E, Chiba C, Bhan AK. Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice. J Exp Med 1996;184:707-715.
38. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 1997;186:1749-1756.
39. Mizoguchi A, et al. Cytokine imbalance and autoantibody production in T cell receptor-alpha mutant mice with inflammatory bowel disease. J Exp Med 1996;183:847-856.
40. Targan SR, Landers CJ, Cobb L, MacDermott RP, Vidrich A. Perinuclear anti-neutrophil cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative colitis patients. J Immunol 1995;155:3262-3267.
41. Radford-Smith GL, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut 2002;51:808-813.
42. Iqbal N, Oliver JR, Wagner FH, Lazenby AS, Elson CO, Weaver CT. T helper 1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis. J Exp Med 2002;195:71-84.
43. Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002;17:629-638.
44. Nieuwenhuis EE, et al. Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice. Proc Natl Acad Sci USA 2002;99:16951-16956.
45. Wirtz S, et al. EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-kappaB activation. J Immunol 2005;174:2814-2824.
46. Abreu MT, et al. TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem 2002;277:20431-20437.
47. Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET, Arditi M. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001;167:1609-1616.
48. Melmed G, et al. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol 2003;170:1406-1415.
49. Vanderlugt CJ, Miller SD. Epitope spreading. Curr Opin Immunol 1996;8:831-836.
50. Fuss IJ, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-1497.
51. + NK-T cells is increased in oxazolone and human ulcerative colitis (UC). Gastroenterology 2003;124:A35.
52. Kojima R, Kuroda S, Ohkishi T, Nakamaru K, Hatakeyama S. Oxazolone-induced colitis in BALB/C mice: a new method to evaluate the efficacy of therapeutic agents for ulcerative colitis. J Pharmacol Sci 2004;96:307-313.
53. Omata F, Birkenbach M, Matsuzaki S, Christ AD, Blumberg RS. The expression of IL-12 p40 and its homologue, Epstein-Barr virus-induced gene 3, in inflammatory bowel disease. Inflamm Bowel Dis 2001;7:215-220.
54. Li J, et al. Visilizumab, a humanized non-FCR binding anti-CD3 monoclonal antibody, induces selective apoptosis of glucocorticoid-insensitive activated T cells much faster than Azathioprine. Gastroenterology 2004;126:S1074.
55. Plevy S, et al. A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative coltiis: results of a phase 1 study. Gastroenterology 2004;126:579.
56. Tsao T, et al. Visilizumab, a humanized non-FCR binding anti-CD3 monoclonal antibody, induces TH2 cytokine bias in human peripheral blood mononuclear cells. Gastroenterology 2004;126:S1073.
57. Papadakis KA, Treyzon L, Abreu MT, Fleshner PR, Targan SR, Vasiliauskas EA. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther 2003;18:741-747.
58. Sands BE, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7:83-88.
59. Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004;16:1167-1171.
60. Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 2004;38:298-301.
61. Su C, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97:2577-2584.
62. Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005;11:213-218.
63. Russell GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr 2004;39:166-170.
64. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-1157.
65. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-211.
66. Billing P, et al. Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am J Pathol 1995;147:979-987.
67. Vidrich A, Lee J, James E, Cobb L, Targan S. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995;15:293-299.
68. Eggena MP, Targan SR, Vidrich A, Clemons DF, Iwanczyk L, Braun J. Histone H1: the UC-specific pANCA target antigen. FASEB J 1996;10:463.
69. Gordon LK, Eggena M, Targan SR, Braun J. Definition of ocular antigens in ciliary body and retinal ganglion cells by the marker antibody pANCA. Invest Ophthalmol Vis Sci 1999;40:1250-1255.
70. Seibold F, Brandwein S, Simpson S, Terhorst C, Elson CO. pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol 1998;18:153-160.
71. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment Gastroenterology 1994;107:1856-1860.
72. Fleshner PR, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 2001;49:671-677.
73. Gionchetti P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-1209.
74. Dubuquoy L, et al. Impaired expression of peroxisome proliferator- activated receptor gamma in ulcerative colitis. Gastroenterology 2003;124:1265-1276.
75. Natori H, Utsunomiya J, Yamamura T, Benno Y, Uchida K. Fecal and stomal bile acid composition after ileostomy or ileoanal anastomosis in patients with chronic ulcerative colitis and adenomatosis coli. Gastroenterology 1992;102 (Pt 1):1278-1288.
76. Lohmuller JL, Pemberton JH, Dozois RR, Ilstrup D, van Heerden J. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg 1990;211:622-627 (Discussion 627-629).
77. Das KM, Dasgupta A, Mandal A, Geng X. Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanism for ulcerative colitis. J Immunol 1993;150:2487-2493.
78. Cho JH, et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci USA 1998;95:7502-7507.